Even before Sovaldi, the first modern antiviral medicine for Hepatitis C, obtained FDA's market authorisation, a group of scientists from University of Liverpool correctly predicted the looming problem – Hepatitis C drugs will become one of the costliest and thus hardly accessible drugs on the planet. Dr. Andrew Hill and his team from the Department […]
